Spark Therapeutics co-founder back at the helm of a Philadelphia gene therapy company
Almost five years after leaving Spark Therapeutics, Dr. Katherine High is back at the helm of a gene therapy company with ...
pharmaphorum8d
FDA makes history, approving Spark's eye gene therapy
It looked likely that the FDA would approve the US biotech’s Luxturna (voretigene neparvovec) after getting unanimous recommemdation from an expert committee in October. But now the FDA has ...
pharmaphorum4y
First UK patients get Novartis’ Luxturna gene therapy for blindness
The first NHS patients have started treatment with Novartis’ Luxturna, a gene therapy for a sight-robbing inherited disease, after the drugmaker agreed a discount on its £613,000 list price ...
Nature6y
Growing pains for gene therapy manufacturing
In December 2017, the US Food & Drug Administration (FDA) approved Luxturna from Spark Therapeutics — the first gene therapy to win market approval in the US. Several other gene therapy programs ...